Thursday 15 May 2014

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline Review, H1 2014




This report provides comprehensive information on the therapeutic development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) and special features on late-stage and discontinued projects.


Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.


Scope

  • The report provides a snapshot of the global therapeutic landscape of Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
  • The report reviews key players involved in the therapeutics development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects 
  • A review of the Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products



Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Contact US:
Office: United States
State Tower
90 State Street, Suite 700
Albany, NY 12207
United States

Toll Free: 866-997-4948
Tel: +1-518-618-1030
E: 
sales@marketresearchreports.biz



2 comments:

  1. How I became a happy woman again
    With tears of joy and happiness I am giving out my testimony to all viewers on line, my problem with Stomach Cancer stage IB and HIV has caused me many pains and sadness especially in my family.
    I was so afraid of loosing my life, I suffered the embarrassment of visiting
    therapy hundreds of times, unfortunately they did not find a definitive solution to my problem, I cried all day and night, do I have to live my life this way? I searched all true the internet for care, I was scammed by internet fraudsters times without numbers… until a friend of mine who stays in the UK introduced me to a friend of hers who was cured of the same disease, and she introduced me to Dr Itua who cured her from Breast Cancer by this email/WhatsApp +2348149277967,  drituaherbalcenter@gmail.com. I contacted him and he promised that all will be fine and I had faith.He sent me his herbal medicines through Courier service and i was instructed on how to drink it for three weeks to cure,I followed the instruction given to me and Today am a happy woman again. He cures all kind of diseases like,Brain cancer,Gestational trophoblastic disease,Head and neck cancer,Ovarian cancer,Hodgkin lymphoma,Herpes,,Liver cancer,Throat cancer,Syndrome Fibrodysplasia Ossificans ProgresS sclerosis,Alzheimer's disease,Chronic Diarrhea,Copd,Parkinson,Als,Adrenocortical carcinoma  Infectious mononucleosis,Intestinal cancer,Thyroid Cancer,Uterine cancer,Fibroid,Angiopathy, Ataxia,Arthritis,Amyotrophic Lateral Sclerosis,Brain Tumor,Fibromyalgia,Fluoroquinolone ToxicityBladder cancer,Hiv,Esophageal cancer,Gallbladder cancer,Kidney cancer,Hpv,Lung cancer,Melanoma,Mesothelioma,Multiple myeloma,Neuroendocrine tumors
    Non-Hodgkin lymphoma,Oral cancer,Sinus cancer,Hepatitis A,B/C,Skin cancer,Soft tissue sarcoma,Spinal cancer,Stomach cancer,Vaginal cancer,Vulvar cancer,Testicular cancer,Tach Diseases,Leukemia.

    ReplyDelete
  2. We would like to acknowledge the exceptional service that we received during the entire refinancing process. Mr Pedro professionalism and knowledge of the loan company was impressive and truly appreciated. Mr Pedro is a reliable loan officer.In the past, we have had experience with several other banks and have found the process frustrating and tedious. Mr Pedro went above and beyond to ensure that all of our needs were met and that everything was handled thoroughly and efficiently. We have and will continue to recommend him in the future.”Mr Pedro Contact Email pedroloanss@gmail.com

    ReplyDelete